期刊文献+

沙利度胺与柳氮磺吡啶治疗强直性脊柱炎的疗效比较 被引量:2

Analysis of Curative Effect by Thalidomide and Sulfasalazine in the Treatment of Ankylosing Spondylitis
下载PDF
导出
摘要 目的对比沙利度胺与柳氮磺吡啶治疗强直性脊柱炎的疗效。方法 40例强直性脊柱炎患者随机分为实验组和对照组,每组20例。实验组采用沙利度胺治疗,对照组采用柳氮磺吡啶治疗,观察两组患者的C反应蛋白、红细胞沉降率、D-二聚体、Bath强直性脊柱炎功能指数(BASFI)、外周关节肿胀数、扩胸度及临床症状缓解时间的情况。结果实验组的各项指标在治疗后均优于对照组(P<0.05)。结论沙利度胺治疗强直性脊柱炎能够有效缓解症状,疗效显著。 Objective To analyze the clinical effect by thalidomide and sulfasalazine in the treatment of ankylosing spondylitis(AS). Methods A total of 40 patients with ankylosing spondylitis were randomly divided into experimental group and control group,with 20 cases in each group. The experimental group given thalidomide for treatment,and the control group given sulfasalazine for treatment for treatment. C-reactive protein,erythrocyte sedimentation rate,D-dimer,Bath Ankylosing Spondylitis Functional Index(BASFI),peripheral swollen joint count,chest expansion degree,and clinical relief time in both groups were observed. Results The experimental group had all better indexes after treatment than the control group(P〈0.05).Conclusion Thalidomide can effectively relieve symptoms in treating ankylosing spondylitis,along with precisely curative effect.
出处 《中国卫生标准管理》 2016年第24期106-108,共3页 China Health Standard Management
关键词 强直性脊柱炎 沙利度胺 柳氮磺吡啶 疗效 Ankylosing spondylitis Thalidomide Sulfasalazine Curative effect
  • 相关文献

参考文献10

二级参考文献103

  • 1赵福涛,丁元晶,赵浩.柳氮磺吡啶、甲氨喋呤及二者合用治疗强直性脊柱炎的临床研究[J].重庆医学,2006,35(22):2060-2062. 被引量:2
  • 2赵福涛,赵浩.甲氨蝶呤与柳氮磺吡啶治疗强直性脊柱炎的临床对比研究[J].实用医学杂志,2007,23(8):1231-1233. 被引量:5
  • 3雷莹辉,裴志刚,高国红.强直性脊柱炎并发的心脏病变[J].中国疗养医学,2007,16(6):365-365. 被引量:2
  • 4李军霞,刘晶,张莉芸,张改莲,李小峰.强直性脊柱炎与T细胞亚群及其细胞因子的研究现状[J].临床医药实践,2007,16(6):403-406. 被引量:4
  • 5陆再英,钟南山.内科学[M].北京:人民卫生出版社,2008:121.
  • 6Bloom BJ,Tucker LB,Miller LC,et al. Fibrin D-dimer as a marker of disease activity in systemic onset juvenile rheumatoid arthritis [ J ]. J Rheumatol, 1998,25 ( 8 ) : 1620 - 1625.
  • 7So AK,Variseo PA, Kemkes-Matthes B, et al. Arthritis is linked to lacal and systemic activation of coagulation and fibrinolysis pathways [J]. J Thmmb Hacmost ,2003, 1:2510 - 2515.
  • 8Jin T, Bokarewa M, Ainu S, et al. Impact of short-term therapies with biologics on prothrombotie biomarkers in rhcumatoid arthritis[J]. Clin Exp Rheumatol,2009,27 ( 3 ) :491 - 494.
  • 9Ingegnoli F, Fantini F, Favalli EG, et al. Inflammatory and prothrom+ botie biomarkers in patients with rheumatoid arthritis;effecots of tumor necrosis factor-alpha blockade[J]. J Autoimmun ,2008,31 ( 2 ) : 175 179.
  • 10Robson SC,Shephard EG,Kitsch RE. Fibrin degradalion produet D-dimet induces the synthesis and release of biologieatly active IL-1 beta IL-6 and plasminogen activator inhibitors from monacyte in vitro [J]. Br J Huematol , 1994,86:322 - 326.

共引文献952

同被引文献19

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部